Ligandin was decreased by 75% as determined immunologically and by glutathione-S-transferase or steroid isomerase activities in rat hepatocellular carcinomas induced by exposure to N-2-fluorenylacetamide. Minor variable differences in ligandin levels were noted between the putative, premalignant nodules induced by this regimen and normal liver.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000225675 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Aloe arborescens Standardized Glycosidic Fraction Suppresses Hepatocarcinoma by Modulating TIMP1, MMP9 Genes Expression, and Inflammation/Ki67/TGFβ1 Pathway.
Phytother Res
December 2024
Department of Forensic Medicine and Toxicology, Faculty of Veterinary Medicine, Benha University, Toukh, Egypt.
(1) Background and aim: Aloe arborescens Mill. (A. arborescens) is one of the most widely distributed species in the genus Aloe and has garnered widespread recognition for its anticancer properties.
View Article and Find Full Text PDFGlutathione and Selenium Supplementation Attenuates Liver Injury in Diethylnitrosamine-Induced Hepatocarcinogenic Mice by Enhancing Glutathione-Related Antioxidant Capacities.
Int J Mol Sci
October 2024
Department of Nutrition, Chung Shan Medical University, Taichung 40201, Taiwan.
Excess oxidative stress and inadequate antioxidant capacities are critical features in the development of hepatocellular carcinoma. This study aimed to determine whether supplementation with glutathione (GSH) and/or selenium (Se), as antioxidants, attenuates diethylnitrosamine (DEN)-induced hepatocarcinogenesis in mice. C57BL/6J male mice were randomly assigned to control, DEN, DEN + GSH, DEN + Se, and DEN + GSH + Se groups for 20 weeks.
View Article and Find Full Text PDFGSTA1/CTNNB1 axis facilitates sorafenib resistance via suppressing ferroptosis in hepatocellular carcinoma.
Pharmacol Res
December 2024
College of Chemistry and Life Science, Beijing University of Technology, Beijing 100124, China; Beijing Molecular Hydrogen Research Center, Beijing 100124, China. Electronic address:
The emergence of sorafenib resistance has become a predominant impediment and formidable dilemma in the therapeutic approach for hepatocellular carcinoma (HCC). Although the approval of next-generation drugs as alternatives to sorafenib is a significant development, the concurrent use of inhibitors that target additional key molecular pathways remains an effective strategy to mitigate the acquisition of resistance. Here, we identified Glutathione S-Transferase Alpha 1 (GSTA1) as a critical modulator of sorafenib resistance (SR) in hepatocellular carcinoma (HCC) based on our findings from experiments conducted on recurrent liver cancer tissues, xenograft mouse models, organoids, and sorafenib-resistant cells.
View Article and Find Full Text PDFAnti-viral and Apoptotic Induction of m-TOR Inhibitor Drugs against Hepatitis C Virus Activity and Hepatocellular Carcinoma Cell Line: In vitro and in silico.
Asian Pac J Cancer Prev
October 2024
Department of Zoology, Faculty of Science, Cairo University, Giza 12613, Egypt.
Article Synopsis
- - The study examined the effectiveness of m-TOR inhibitors (sirolimus, everolimus, tacrolimus) in treating hepatocellular carcinoma (HCC) and hepatitis C virus (HCV) replication by assessing various cellular activities and markers in specific cell lines.
- - Results showed that these inhibitors reduced cell viability in HCC cells, induced apoptosis, and halted cell cycle progression, while also significantly lowering HCV viral load in infected cells, indicating their potential for dual therapeutic applications.
- - Molecular docking studies suggested that Sovaldi had the strongest binding to HCV targets, highlighting the promise of m-TOR inhibitors in advancing both HCC and HCV treatment strategies in the future.
Cabozantinib prevents the progression of metabolic dysfunction-associated steatohepatitis by inhibiting the activation of hepatic stellate cell and macrophage and attenuating angiogenic activity.
Heliyon
October 2024
Department of Gastroenterology, Nara Medical University, Kashihara, Nara, 634-8521, Japan.
Article Synopsis
- * In rats fed a special high-fat diet, cabozantinib treatment significantly decreased liver inflammation and fibrosis but did not change fat accumulation in liver cells, indicating its targeted impact on fibrosis rather than overall liver health.
- * The study found that cabozantinib reduced certain harmful liver cell activations and inflammatory responses without hindering liver cell regeneration, suggesting its potential for aiding liver health in cancer treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!